BACKGROUND: Primary spinal cord tumors (PSCTs) in pediatric patients are rare, with a reported overall incidence rate of 1-2.6 per one million children. We reviewed our experience of surgically treated 27 pediatric patients with PSCT and discussed the clinical features, radiological findings, surgical outcomes, and prognostic factors. METHODS: Between March 1999 and March 2010, a total of 27 pediatric patients with PSCT were surgically treated in a single institution. We retrospectively analyzed their data. RESULTS: There were 13 females and 14 males, and their ages ranged from 6 months to 19 years (mean age, 12.1 years). The most common presenting symptom was motor weakness, and the histologic type of the tumors were mainly schwannoma, astrocytoma, and ependymoma. The tumor was completely resected in 17 patients, subtotally resected in 7 patients, and partial resection or biopsy was performed in 3 patients. Adjuvant chemotherapy was performed in 9 patients, and radiotherapy in 12 patients, respectively. The average follow-up period was 33.5 months (1.17-129). Five patients experienced the progression of disease, and three of them expired. The mean time for disease progression was 19.0 months (4.5-48.7). CONCLUSIONS: PSCT in pediatric patients can be surgically removed with an acceptable low surgical morbidity. Progression-free survival was found to be related to the grade of tumor and the extent of tumor resection. Early diagnosis and treatment anticipate good functional neurologic outcome.
BACKGROUND: Primary spinal cord tumors (PSCTs) in pediatric patients are rare, with a reported overall incidence rate of 1-2.6 per one million children. We reviewed our experience of surgically treated 27 pediatric patients with PSCT and discussed the clinical features, radiological findings, surgical outcomes, and prognostic factors. METHODS: Between March 1999 and March 2010, a total of 27 pediatric patients with PSCT were surgically treated in a single institution. We retrospectively analyzed their data. RESULTS: There were 13 females and 14 males, and their ages ranged from 6 months to 19 years (mean age, 12.1 years). The most common presenting symptom was motor weakness, and the histologic type of the tumors were mainly schwannoma, astrocytoma, and ependymoma. The tumor was completely resected in 17 patients, subtotally resected in 7 patients, and partial resection or biopsy was performed in 3 patients. Adjuvant chemotherapy was performed in 9 patients, and radiotherapy in 12 patients, respectively. The average follow-up period was 33.5 months (1.17-129). Five patients experienced the progression of disease, and three of them expired. The mean time for disease progression was 19.0 months (4.5-48.7). CONCLUSIONS: PSCT in pediatric patients can be surgically removed with an acceptable low surgical morbidity. Progression-free survival was found to be related to the grade of tumor and the extent of tumor resection. Early diagnosis and treatment anticipate good functional neurologic outcome.
Authors: John R Crawford; Alejandra Zaninovic; Mariarita Santi; Elisabeth J Rushing; Cara H Olsen; Robert F Keating; Gilbert Vezina; Nadja Kadom; Roger J Packer Journal: J Neurooncol Date: 2009-06-12 Impact factor: 4.130
Authors: Michael Safaee; Michael C Oh; Joseph M Kim; Derick Aranda; Phiroz E Tarapore; Tene A Cage; Nalin Gupta; Andrew T Parsa Journal: Childs Nerv Syst Date: 2013-05-16 Impact factor: 1.475
Authors: Faris Shweikeh; Carolyn Quinsey; Roger Murayi; Ryan Randle; Miriam Nuño; Mark D Krieger; J Patrick Johnson Journal: Childs Nerv Syst Date: 2017-05-08 Impact factor: 1.475
Authors: Steven S Carey; Zsila Sadighi; Shengjie Wu; Jason Chiang; Giles W Robinson; Yahya Ghazwani; Anthony P Y Liu; Sahaja Acharya; Thomas E Merchant; Frederick A Boop; Amar Gajjar; Ibrahim Qaddoumi Journal: J Neurooncol Date: 2019-10-22 Impact factor: 4.130
Authors: Philip J O'Halloran; Michael Farrell; John Caird; Michael Capra; David O'Brien Journal: Childs Nerv Syst Date: 2013-01-15 Impact factor: 1.475
Authors: Zsila S Sadighi; Elizabeth Curtis; Jennifer Zabrowksi; Catherine Billups; Amar Gajjar; Raja Khan; Ibrahim Qaddoumi Journal: Pediatr Blood Cancer Date: 2018-05-09 Impact factor: 3.167